logo

For the Inventor, By the Inventor

Menlo Park, CA, United States of America

Patrick J Lupardus

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:

goldMedal15 out of 18 
 
Synthekine, Inc.
 patents

Years Active: 2024-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 12448457 - GP130 binding molecules and methods of use (2025-10-21),
2. 12297281 - IL10RA binding molecules and methods of use (2025-05-13),
3. 12291572 - IL12 receptor synthetic cytokines and methods of use (2025-05-06),
4. 12286482 - IL10RB binding molecules and encoding nucleic acids (2025-04-29),
5. 12234291 - IL2RB binding molecules and methods of use (2025-02-25),
6. 12209132 - Compositions and methods related to IL27 receptor binding (2025-01-28),
7. 12157773 - IL27RAlpha binding molecules and methods of use (2024-12-03),
8. 12139545 - IL10 receptor binding molecules and methods of use (2024-11-12),
9. 12122839 - IFNGR binding synthetic cytokines and methods of use (2024-10-22),
10. 12103954 - Heterodimeric Fc cytokines and uses thereof (2024-10-01),
11. 12077594 - IL2RG binding molecules and methods of use (2024-09-03),
12. 12018085 - Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases (2024-06-25),
13. 12012457 - IL23R binding molecules and methods of use (2024-06-18),
14. 11873349 - Compositions and methods related to IL27 receptor binding (2024-01-16),
15. 11859001 - IL12RB1-Binding molecules and methods of use (2024-01-02),

Title: **Innovative Contributions of Patrick J Lupardus in Biologics**

Introduction

Patrick J Lupardus, an inventive mind based in Menlo Park, California, has made significant strides in the field of biologics with a remarkable portfolio of 14 patents. His work primarily focuses on therapeutic molecules and methods that are critical for advancing medical treatments.

Latest Patents

Among his latest contributions, Patrick developed technologies involving IL10RA binding molecules and methods of use. This innovation centers around biologically active molecules containing a single domain antibody (sdAb) that selectively binds to the extracellular domain of human IL10Ra. These antibodies hold potential therapeutic applications that could revolutionize treatment methods. Furthermore, his patent on IL12 receptor synthetic cytokines introduces IL12R binding molecules that interact with IL12Rb1 and IL12Rb2, incorporating an anti-IL12Rb2 sdAb and an anti-IL12Rb2 VH antibody, highlighting his inventive capabilities in cytokine therapy.

Career Highlights

Patrick’s career is marked by his role at Synthekine, Inc., a company renowned for its innovative approaches in the biotechnology space. His extensive experience and expertise have led to significant advancements in therapeutic technologies, contributing to the health sector's progress.

Collaborations

Throughout his professional journey, Patrick has collaborated with esteemed colleagues such as Deepti Rokkam and Robert Kastelein. These partnerships foster an environment of mutual growth and knowledge sharing, further enhancing the innovation landscape in which they operate.

Conclusion

Patrick J Lupardus continues to be a pivotal figure in biologics innovation, with his ongoing work promising groundbreaking advancements in medical science. His contributions not only reflect his dedication as an inventor but also his commitment to improving health outcomes through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…